Samuel Gbeminiyi, Atanda Adebayo C, Onyemeh Alex, Awan Ahmad, Ajiboye Oyintayo
Department of Internal Medicine, Howard University Hospital.
Public Health, John Hopkins School of Public Health.
Cureus. 2017 Aug 31;9(8):e1633. doi: 10.7759/cureus.1633.
Dual antiplatelet agents and high-intensity statins are frequently used in combination after myocardial infarction. Ticagrelor has the potential of causing acute kidney injury. Rosuvastatin is excreted through the kidneys and dose adjustment is needed in patients with kidney disease. When used in combination, they can potentiate the toxic effects of each other. We report a case of drug interaction between rosuvastatin and ticagrelor resulting in rhabdomyolysis and acute renal failure necessitating dialysis. This case stresses the importance of monitoring renal function and adjusting the dose of rosuvastatin accordingly in patients with kidney disease.
心肌梗死后，双联抗血小板药物和高强度他汀类药物经常联合使用。替格瑞洛有导致急性肾损伤的可能性。瑞舒伐他汀通过肾脏排泄，肾病患者需要调整剂量。联合使用时，它们可能会增强彼此的毒性作用。我们报告一例瑞舒伐他汀与替格瑞洛药物相互作用导致横纹肌溶解和急性肾衰竭需要透析的病例。该病例强调了在肾病患者中监测肾功能并相应调整瑞舒伐他汀剂量的重要性。
